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Summary  A  70-year-old  man  presented  to  the  emergency  department  at  our  hospital  with
chest pain,  24  months  after  sirolimus-eluting  stents  (SESs)  were  implanted  in  the  proximal  left
anterior descending  coronary  artery  (LAD),  middle  right  coronary  artery  (RCA),  and  middle  left
circumﬂex artery  (LCX),  respectively.  Electrocardiogram  showed  complete  right  bundle  branch
block and  ST-segment  elevation  in  leads  II,  III,  and  aVF.  He  suddenly  went  to  ventricular  tachy-
cardia, followed  by  ventricular  ﬁbrillation.  Administration  of  electrical  shock  led  to  cardiac
arrest. Immediately,  we  inserted  a  percutaneous  cardiopulmonary  system  and  intra-aortic  bal-staining loon pumping.  Subsequent  emergent  coronary  angiography  showed  100%  thrombotic  total  stent
obstruction  of  triple  vessels  with  thrombolysis  in  myocardial  infarction  0  ﬂow.  Thrombectomy
and balloon  angioplasty  were  performed  at  the  in-stent  thrombotic  sites.  Despite  our  intensive
care, he  died  due  to  heart  failure  on  the  third  day  after  hospitalization.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
hIntroductionDrug-eluting  stents  (DESs)  have  dramatically  reduced  the
incidence  of  in-stent  restenosis.  However,  recent  studies
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doi:10.1016/j.jccase.2011.12.004ave  suggested  that  the  implantation  of  DES  is  associated
ith  a  higher  rate  of  very  late  stent  thrombosis  (VLST)  com-
ared  with  bare  metal  stents  (BMS).  The  occurrence  of  VLST
s  uncommon,  but  it  might  be  a fatal  event.  VLST  after  DES
mplantation  has  emerged  as  a  major  concern.  Although
he  mechanisms  of  VLST  after  DES  implantation  are  cur-
ently  very  poorly  understood,  the  association  between  late
cquired  incomplete  stent  apposition  (ISA)  and  VLST  has
een  suggested  by  several  intravascular  ultrasound  (IVUS)
tudies  demonstrating  high  prevalence  of  ISA  in  the  setting
Published by Elsevier Ltd. All rights reserved.
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f  VLST  [1—3]. Moreover,  peri-stent  contrast  staining  (PSS)
as  recently  been  reported  as  a  predisposing  angiographic
nding  for  VLST  [4].  Here,  we  present  a  case  of  simultane-
us  stent  obstruction  of  triple  vessels  with  VLST  following
ES  implantation  after  a  period  of  24  months.
ase report
 70-year-old  man,  who  had  no  past  medical  history,  was
dmitted  to  his  local  community  hospital  with  unstable
ngina  pectoris  in  April  2008.  Urgent  coronary  angiography
howed  90%  stenosis  in  the  proximal  left  anterior  descend-
ng  coronary  artery  (LAD)  segment  6,  90%  stenoses  in  the
iddle  right  coronary  artery  (RCA)  segment  2  and  3  respec-
ively,  and  90%  stenosis  in  the  middle  left  circumﬂex  artery
LCX)  segment  13.  Sirolimus-eluting  stent  (SES)  (Cypher
.0  mm  × 23 mm;  Johnson  &  Johnson,  Cordis  Corporation,
iami,  FL,  USA)  was  deployed  in  LAD,  and  SES  (Cypher
.5  mm  × 23 mm)  was  deployed  in  LCX.  One  month  later,  SES
Cypher  3.0  mm  × 33 mm)  and  SES  (Cypher  3.5  mm  × 23  mm)
ere  electively  implanted  in  RCA  segment  2  and  3,  respec-
ively.  After  angioplasty,  he  had  been  treated  with  dual
ntiplatelet  therapy  (aspirin  100  mg/day  and  ticlopidine
ydrochloride  200  mg/day).
Six  months  later,  follow-up  coronary  angiography  showed
o  in-stent  restenosis  and  fracture  of  four  stents.  How-
ver,  mono-focal  PSS  was  seen  in  the  stented  lesion  of  LAD,
ut  not  in  the  stented  lesions  of  LCX  and  RCA  (Fig.  1).
eft  ventriculography  revealed  normal  contraction  in  all
egments.
He  presented  to  the  emergency  department  at  our  hos-
ital  with  a  chest  pain  in  April  2010.  He  was  asymptomatic
ntil  the  current  episode.  At  the  time  of  presentation,
is  blood  pressure  was  84/66  mmHg.  Arterial  blood  gas
nalysis  showed  hypoxemia  and  mild  metabolic  acidosis.
aboratory  examinations  showed  normal  creatine  kinase,
ut  positive  heart-type  fatty  acid-binding  protein  test  result
nd  elevated  B-type  natriuretic  peptide  level  of  321  pg/mL.
lectrocardiogram  showed  complete  right  bundle  branch
lock  and  ST-segment  elevation  in  leads  II,  III,  and  aVF
Fig.  2).  Transthoracic  echocardiography  demonstrated  dif-
use  hypokinesis  with  left  ventricular  ejection  fraction  of
bout  10%.  He  suddenly  went  to  ventricular  tachycardia,
hich  was  not  terminated  by  an  administration  of  100  mg
f  lidocaine,  followed  by  ventricular  ﬁbrillation.  Electri-
al  shock  was  rapidly  administered,  and  then  he  went
o  cardiac  arrest.  We  started  cardiopulmonary  resuscita-
ion  along  with  the  advanced  cardiopulmonary  life  support
rotocol,  but  cardiac  arrest  persisted.  Immediately,  we
nserted  a  percutaneous  cardiopulmonary  system,  followed
y  intra-aortic  balloon  pumping  and  temporary  pacing.  A
ew  minutes  later,  his  cardiac  rhythm  came  back.  Subse-
uent  emergent  coronary  angiography  demonstrated  100%
hrombotic  total  stent  obstruction  of  triple  vessels  with
hrombolysis  in  myocardial  infarction  (TIMI)  0  ﬂow  (Fig.  3).
 0.014-in.  guidewire  was  easily  crossed  through  the  total
cclusive  sites.  Aspiration  thrombectomy  was  conducted
nto  three  vessels  respectively,  resulting  in  TIMI-3  ﬂow.  And
hen,  balloon  angioplasty  (Tazuna  3.0  mm  ×  15  mm  in  LAD,
azuna  2.5  mm  ×  15  mm  in  LCX,  Tazuna  3.0  mm  ×  15  mm  in
CA,  respectively;  Terumo  Corporation,  Tokyo,  Japan)  was
p
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erformed  at  the  in-stent  thrombotic  sites  and  good  ﬁnal
esults  were  obtained  (Fig.  3).
He  was  previously  prescribed  with  ticlopidine  hydrochlo-
ide  200  mg/day  before  his  admission.  At  the  time  of
ospitalization,  he  had  stopped  taking  his  medications
y  himself  for  an  unknown  period.  After  angioplasty,  he
eceived  dual  antiplatelet  therapy  of  aspirin  100  mg/day  and
lopidogrel  75  mg/day.  Despite  our  intensive  care,  he  died
ue  to  heart  failure  on  the  third  day  after  hospitalization.
iscussion
ES  has  several  advantages  over  BMS  including  signiﬁ-
ant  lower  target  vessel  restenosis  and  revascularization,
hereas  DES  is  associated  with  a  higher  incidence  of  VLST.
lthough  VLST  after  DES  implantation  is  uncommon,  patients
ho  develop  VLST  have  a  poor  prognosis.  Moreover,  VLST  can
ead  to  unexpected  sudden  death.
Stent  thrombosis  (ST)  is  classiﬁed  by  the  Academic
esearch  Consortium  into  four  types  based  on  the  time  of
vent  as:  acute  (within  24  h),  subacute  (24  h  to  30  days),  late
30  days  to  1  year),  and  very  late  (beyond  1  year).  The  major-
ty  (41—60%)  of  ST  events  occur  during  the  ﬁrst  30  days  after
ES  implantation,  followed  by  events  occurring  between  30
ays  and  1  year  (18—37%).  VLST  occurs  at  a  frequency  of
0%  of  the  total  event  rate  per  year,  corresponding  to  an
bsolute  incidence  of  0.4—0.6%/year  [5].
Early  (acute  and  subacute)  ST  is  encountered  with  a  sim-
lar  or  even  somewhat  lower  frequency  after  DES  compared
ith  BMS.  Moreover,  no  signiﬁcant  differences  existed  in
he  incidence  of  late  stent  thrombosis  (LST)  between  DES
nd  BMS  according  to  various  deﬁnitions  as  proposed  by  the
cademic  Research  Consortium  [6].  However,  accumulating
vidence  has  demonstrated  that  VLST  is  more  common  with
ES  than  BMS.  Pooled  analysis  of  4  randomized  trials  (1748
atients)  comparing  SES  and  of  5  randomized  trials  (3513
atients)  comparing  paclitaxel-eluting  stent  (PES)  with  BMS
evealed  similar  rates  of  ST  up  to  1  year  but  signiﬁcantly
ore  VLST  (SES  versus  BMS:  0.6%  versus  0%,  p  =  0.03;  PES
ersus  BMS:  0.7%  versus  0.2%,  p  =  0.03)  [7].  Furthermore,
nother  systematic  review  of  14  trials  comparing  SES  with
MS  revealed  no  difference  in  the  overall  incidence  of  ST
SES  versus  BMS:  1.5%  versus  1.3%,  p  =  0.75),  but  VLST  was
ore  frequent  with  SES  (SES  versus  BMS:  0.3%  versus  0.04%,
 =  0.02)  [8].  These  results  suggest  that  the  predominant
echanisms  might  be  different  between  LST  and  VLST.
Although  the  mechanisms  of  VLST  after  DES  implantation
re  currently  very  poorly  understood,  several  IVUS  studies
evealed  that  late  acquired  ISA  with  positive  remodeling  was
ore  frequent  in  patients  with  VLST  compared  with  con-
rol  subjects  [1,3]. Moreover,  eosinophilic  inﬁltrates  were
ore  common  in  thrombi  harvested  from  patients  with  VLST
ompared  with  other  causes  of  myocardial  infarction  [2].
hese  observations  were  consistent  with  chronic  inﬂam-
ation  and/or  hypersensitivity  reported  in  several  autopsy
ases  after  DES  implantation,  suggesting  the  presence  of
rofound  chronic  inﬂammation  with  ISA  and  positive  remod-
ling  as  one  of  the  most  dominant  mechanisms  of  VLST.
urthermore,  the  de  novo  atherosclerosis  was  reported  to
e  seen  earlier  and  more  frequently  in  lesions  treated  with
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Figure  1  Follow-up  angiographic  ﬁndings.  Arrow  head  shows  peri-stent  contrast  staining  in  the  left  anterior  descending  artery
stented lesion.
Figure  2  At  the  time  of  presentation,  his  electrocardiogram  showed  complete  right  bundle  branch  block  and  ST-segment  elevation
in leads  II,  III,  and  aVF.
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Figure  3  Emergent  coronary  angiography  showed  100%  thrombotic  total  obstruction  of  all  stents  with  thrombolysis  in  myocardial
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ES  compared  with  those  treated  with  BMS  [9].  Those  de
ovo  atherosclerotic  plaques  might  be  susceptible  to  VLST.
Abnormal  vessel  wall  responses  manifesting  as  coronary
rtery  aneurysm  were  demonstrated  by  coronary  angiogra-
hy  after  DES  implantation  in  several  case  reports  [10,11].
s  well  as  coronary  artery  aneurysm  formation,  PSS  was  cur-
ently  reported  as  a  predisposing  angiographic  ﬁnding  for
LST.  PSS  was  deﬁned  as  contrast  staining  outside  the  stent
ontour  extending  to  ≥20%  of  the  stent  diameter,  measured
y  quantitative  coronary  angiography  [4].  Because  this  type
f  contrast  staining  outside  the  stent  struts  very  rarely  had
een  seen  after  BMS  implantation,  PSS  could  be  regarded  as
epresenting  an  abnormal  vessel  wall  response  to  DES.  Inci-
ence  of  deﬁnite  VLST  in  patients  with  PSS  was  higher  than
hat  in  patients  without  PSS.  The  prevalence  of  stent  frac-
ure  in  lesions  with  PSS  was  also  higher  than  that  in  lesions
ithout  PSS.  In  this  case,  follow-up  coronary  angiography
howed  monofocal  PSS,  but  no  stent  fracture  in  the  stented
esion  of  LAD.
Discontinuation  of  dual  antiplatelet  therapy  has  emerged
s  one  of  the  most  important  predictors  of  ST.  It  was
eported  that  the  patients  undergoing  multivessel  stenting
ere  susceptible  to  multivessel  ST  [12]. Stringent  compli-
nce  and  adherence  to  antiplatelet  therapy  seems  to  be
articularly  important  in  patients  undergoing  multivessel
tenting.
i
c
v
my  were  performed  at  the  in-stent  thrombotic  sites,  resulting  in
VLST  is  a  serious  complication  that  usually  leads  to
yocardial  infarction  or  sudden  death.  In  the  present  case,
LST-induced  obstruction  of  three  stents  resulted  in  a  fatal
utcome.  Some  possible  reasons  may  contribute  to  VLST.
irst,  although  this  patient  was  prescribed  with  antiplatelet
herapy  (ticlopidine  hydrochloride  200  mg/day),  he  stopped
aking  his  medications  by  himself.  Second,  PSS  was  seen
n  LAD  stented  lesion  by  follow-up  coronary  angiogra-
hy,  suggesting  the  presence  of  chronic  inﬂammation
nd/or  hypersensitivity  response  to  SES.  Thrombus  for-
ation  in  LAD  stented  lesion  might  be  the  trigger  of
LST  in  other  stented  lesions  through  several  mechanisms,
ncluding  activation  of  platelets.  At  the  emergency  depart-
ent,  his  electrocardiogram  showed  ST-segment  elevation
n  leads  II,  III,  and  aVF.  However,  since  echocardiography
emonstrated  diffuse  hypokinesis  of  left  ventricle,  unsta-
le  thrombus  formations  might  already  have  existed  in
hree  vessels  at  his  presentation.  Unfortunately,  we  did
ot  have  IVUS  or  optical  coherence  tomography  images
o  provide  the  information  of  ISA  and  positive  arterial
emodeling.
Caution  should  be  exercised  in  patients  undergoing  DES
mplantation,  especially  multivessel  stenting.  Finally,  this
ase  highlights  the  need  of  the  determination  of  the  pre-
entive  recommendation  for  VLST  in  patients  undergoing
ultivessel  DES  implantation.
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